Skip to content

About us

Who we are

Biosimilars Canada is a national association representing the biosimilar medicines industry in Canada. Our member companies are at the forefront of the global development and marketing of biosimilar medicines.

Biosimilars Canada provides leadership in educating Canadian stakeholders about the safety and efficacy of biosimilar medicines, and advocates for policies that support their timely approval, reimbursement, market acceptance and expanded use. Maximizing the use of biosimilar medicines provides a significant contribution to the sustainability of drug plans and healthcare systems while supporting positive patient outcomes.

In collaboration with its partners in the International Generic and Biosimilar Medicines Association (IGBA), Biosimilars Canada seeks to address global developments for the biosimilar medicines industry and participates in initiatives to raise the domestic and global awareness of biosimilar medicines such as Global Biosimilars Week. Biosimilars Canada is a division of the Canadian Generic Pharmaceutical Association.

Biosimilars Canada Board

Michel Robidoux, Sandoz – Chair

Mike Woolcock, Apobiologix – Vice Chair

Jeff Watson, Apotex

Suresh Kalidoss, Auropharma Inc.

Matthew Rotenberg, Fresenius Kabi

Jean-Guy Goulet, Pharmascience

Barb Pimentel, Taro

Benjamin Gray, Teva

Christine Poulin, Teva

David Simpson, Viatris

Jim Keon, Biosimilars Canada (Ex-Officio)

Member companies